AGP Executive Report
Last update: 4 hours agoCancer Care: The European Commission approved Rasonque for adults with metastatic pancreatic cancer after at least one prior treatment. The authorisation covers the EEA, including Liechtenstein, but patient access depends on local pricing and reimbursement. Sepalna was also approved in Europe as maintenance therapy for some patients with advanced ovarian cancer; its commercial rights include Liechtenstein. More Treatment Options: EU regulators recommended Zybrivo with chemotherapy as a first-line option for advanced non-squamous lung cancer, and belzutifan plus lenvatinib for advanced kidney cancer after immunotherapy. Both still need European Commission approval. Public Health: The ECDC is preparing a multilingual surveillance platform to help European countries spot and assess emerging health threats, with rollout planned for next year.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.